Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals completes a $705.8 million stock offering.
1 source·11/12, 12:50·sec.gov
Positive CARDINAL trial results for TERN-701 announced.
1 source·08/12, 21:02·sec.gov
10-Q form submitted!
1 source·10/11, 21:33·sec.gov
Announcement of quarterly financial results filing.
1 source·10/11, 21:18·sec.gov
Positive clinical data for TERN-701 presentation announced.
1 source·03/11, 14:20·sec.gov
Terns announces positive Phase 2 results for TERN-601.
1 source·22/10, 10:03·sec.gov
10-Q form submitted!
1 source·05/08, 20:33·sec.gov
Routine financial results disclosed in 8-K filing.
1 source·05/08, 20:20·sec.gov
Routine proposals approved in annual stockholder meeting.
1 source·16/06, 20:28·sec.gov
Terns Pharmaceuticals to attend June investor conferences.
1 source·29/05, 20:08·finviz.com
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
·finviz.com·14/05, 13:35
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?
·finviz.com·09/05, 12:00
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
·finviz.com·02/05, 20:15
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
·globenewswire.com·30/04, 20:08
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
·finviz.com·07/04, 14:41
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
·globenewswire.com·02/04, 20:18